Biotech Startups

evitria provides custom recombinant antibody production in CHO cells, covering standard IgGs, bispecific, afucosylated, Fc-silenced, and high-throughput formats, as well as non-antibody proteins. It serves biotech and pharma customers worldwide for research and development, from early discovery through larger-scale studies.

1 investor

Evoke Pharma develops treatments for gastrointestinal disorders, focusing on advancing and commercializing GIMOTI, a nasal spray formulation for diabetic gastroparesis. The company operates in the pharmaceutical and specialty care industry.

1 investor

Evolutionary Genomics applies genomic analysis and molecular selection detection to advance research in animal science, oncology, and infectious disease therapeutics. The company develops algorithms and research programs for identifying genetic targets and understanding molecular-level evolutionary processes.

1 investor

EvolutionaryScale develops artificial intelligence models for biology, including ESM3, a family of models that reason over protein sequence, structure, and function to help scientists understand and design novel proteins. Its models are offered to the scientific community through an API and partner platforms, with a smaller open model available under a non-commercial license.

1 investor

Evolvere BioSciences develops antibiotics using computational models and evolutionary data to target pathogenic bacteria while preserving beneficial microbes, designed to resist the development of bacterial resistance.

1 investor

Evotec is a drug discovery and development company that uses scientific research, technologies, and partnerships to accelerate the discovery and delivery of new therapies. It serves the pharmaceutical and biotech sector by advancing medical treatments for patients.

1 investor

Evoxx technologies is a research-driven enzyme and probiotic manufacturer offering enzymatic solutions for human nutrition, animal nutrition, bio-processing, and pharmaceutical industries. As the European subsidiary of Advanced Enzymes Technologies Ltd., it develops proprietary enzymes and supports customers from concept through production and deregulation.

1 investor

Exactmer develops organic solvent-stable nanofiltration (OSN) membranes and a liquid-phase synthesis platform for pharmaceutical manufacturers, aimed at lower-cost and more scalable production of oligonucleotide and other advanced polymer therapeutics. It serves drug developers working with chemistries such as ASO, siRNA, peptides, ADC linkers, and PEGs.

1 investor

ExAI develops technology for early cancer detection, diagnosis, and management. The company serves healthcare providers and patients in the oncology space.

1 investor

Exapto develops engineered biocomponents — novel patented metabolic pathways and enzymes — for industrial biomanufacturing, aimed at improving existing bioproductions and enabling access to chemicals that were previously unreachable from renewable resources. The company combines synthetic biology and AI in its R&D stack to produce key chemicals for the biomanufacturing industry.

1 investor

Excel Venture Management is a venture capital firm that invests in healthcare and life sciences companies across various sectors and stages, with a focus on businesses that lower costs and improve outcomes.

1 investor

Excite Pharma is an FDA-inspected, GMP/GLP-compliant contract research and manufacturing organization providing CMC services to pharmaceutical companies, with a focus on aseptic manufacturing and analytical chemistry across drug substance, drug product, and excipients. Its services span small-scale development, clinical and commercial manufacturing, method development and validation, stability programs, release testing, dissolution, residual solvent and metal analysis, and extractables and leachables testing.

1 investor

Exciting Instruments builds the EI-FLEX benchtop platform, a single-molecule fluorescence instrument combining smFRET, FCS and FCCS to measure biomolecular interactions and dynamics directly in solution. It serves academic and industry researchers in life science research, drug development, and clinical diagnostics.

1 investor

Exela Pharma Sciences operates cGMP-compliant contract development and manufacturing organization (CDMO) and fill-finish facilities producing injectable pharmaceuticals including vials, pre-filled syringes, and IV bags. The company serves pharmaceutical manufacturers seeking US-based contract manufacturing and development services.

1 investor

Exelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.

1 investor

Exicure is a publicly-traded holding company that previously developed nucleic acid therapies and has since divested its historical biotechnology assets; it is now pursuing growth through acquisitions and partnerships, including a recent investment in GPCR Therapeutics USA, which is developing small molecule therapies for blood cancers and multiple myeloma.

1 investor

Eximia Research operates a nationwide clinical research network that conducts clinical trials, managing patient recruitment, enrollment, and trial operations on behalf of pharmaceutical sponsors and CRO partners. Its sites are overseen by board-certified physician investigators who run regulated studies evaluating new treatments.

1 investor

ExOcular develops blood-based multiplex tests that measure biomarkers isolated from exosomes to detect and monitor severe eye diseases such as diabetic retinopathy and age-related macular degeneration. Its analysis algorithms produce a quantitative Disease Severity Score to help physicians risk-stratify patients and track treatment effectiveness.

1 investor

Exogenus develops therapeutic exosomes derived from umbilical cord blood cells to treat autoimmune diseases through immune system rebalancing. The company targets multiple autoimmune disease indications where existing pharmaceutical treatments carry significant side effects.

1 investor

Exolvo Biosciences develops drug delivery technology. The page does not provide sufficient detail about the company's specific products, markets served, or business model beyond the co-founder's background.

1 investor

Exosomm is a biotechnology company that extracts and standardizes bioactive milk exosomes into commercial ingredients for advanced nutrition and supplement brands. The company licenses these bioactive compounds as a differentiated platform for premium health and wellness products.

1 investor

Expedition Medicines is a drug discovery company developing small-molecule covalent medicines for targets considered 'undruggable', using proprietary proteomic data, AI, and quantum chemistry to design molecules that bind previously inaccessible protein surfaces. Its pipeline includes first-in-class programs in oncology, immunology, and other diseases.

1 investor

Expedition Therapeutics is a drug development company focused on advancing therapeutic programs in areas such as CAR-T immunotherapy and oncology. The company serves patients and healthcare systems seeking novel treatment options.

1 investor

Experic is a CDMO (Contract Development and Manufacturing Organization) specializing in inhalation pharmaceutical product development, formulation engineering, and clinical manufacturing services. The company provides process development, analytical testing, technology transfer, and scale-up support for inhalation drugs and encapsulated solid dose pharmaceuticals.

1 investor